chr20-57331870-G-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_012444.3(SPO11):c.169G>A(p.Asp57Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00000436 in 1,606,046 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/23 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
SPO11
NM_012444.3 missense
NM_012444.3 missense
Scores
1
18
Clinical Significance
Conservation
PhyloP100: 4.67
Genes affected
SPO11 (HGNC:11250): (SPO11 initiator of meiotic double strand breaks) Meiotic recombination and chromosome segregation require the formation of double-strand breaks (DSBs) in paired chromosome homologs. During meiosis in yeast, a meiotic recombination protein is covalently-linked to the 5' end of DSBs and is essential for the formation of DSBs. The protein encoded by this gene is similar in sequence and conserved features to the yeast meiotic recombination protein. The encoded protein belongs to the TOP6A protein family. Several transcript variants encoding different isoforms have been found for this gene, but the full-length nature of only two of them have been described. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPO11 | ENST00000371263.8 | c.169G>A | p.Asp57Asn | missense_variant | 2/13 | 1 | NM_012444.3 | ENSP00000360310.3 | ||
SPO11 | ENST00000345868.8 | c.132-1318G>A | intron_variant | 1 | ENSP00000316034.4 | |||||
SPO11 | ENST00000418127.5 | c.103G>A | p.Asp35Asn | missense_variant | 2/10 | 3 | ENSP00000413185.1 | |||
SPO11 | ENST00000371260.8 | c.132-1318G>A | intron_variant | 5 | ENSP00000360307.4 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152052Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
5
AN:
152052
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000403 AC: 1AN: 248042Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134216
GnomAD3 exomes
AF:
AC:
1
AN:
248042
Hom.:
AF XY:
AC XY:
0
AN XY:
134216
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000138 AC: 2AN: 1453994Hom.: 0 Cov.: 29 AF XY: 0.00000138 AC XY: 1AN XY: 723244
GnomAD4 exome
AF:
AC:
2
AN:
1453994
Hom.:
Cov.:
29
AF XY:
AC XY:
1
AN XY:
723244
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152052Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74298
GnomAD4 genome
AF:
AC:
5
AN:
152052
Hom.:
Cov.:
33
AF XY:
AC XY:
4
AN XY:
74298
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 02, 2024 | The c.169G>A (p.D57N) alteration is located in exon 2 (coding exon 2) of the SPO11 gene. This alteration results from a G to A substitution at nucleotide position 169, causing the aspartic acid (D) at amino acid position 57 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;.
PrimateAI
Benign
T
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Benign
T;T
Sift4G
Benign
T;T
Polyphen
B;.
Vest4
MutPred
Loss of catalytic residue at D57 (P = 0.0842);.;
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: -37
Find out detailed SpliceAI scores and Pangolin per-transcript scores at